Innate Pharma (France) Price Prediction
| IPH Stock | EUR 1.53 0.05 3.16% |
Oversold Vs Overbought
26
Oversold | Overbought |
Using Innate Pharma hype-based prediction, you can estimate the value of Innate Pharma from the perspective of Innate Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Innate Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Innate because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Innate Pharma after-hype prediction price | EUR 1.53 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Innate |
Innate Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Innate Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Innate Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Innate Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Innate Pharma Estimiated After-Hype Price Volatility
In the context of predicting Innate Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Innate Pharma's historical news coverage. Innate Pharma's after-hype downside and upside margins for the prediction period are 0.08 and 3.86, respectively. We have considered Innate Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Innate Pharma is risky at this time. Analysis and calculation of next after-hype price of Innate Pharma is based on 3 months time horizon.
Innate Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Innate Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innate Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Innate Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.47 | 2.33 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.53 | 1.53 | 0.00 |
|
Innate Pharma Hype Timeline
Innate Pharma is currently traded for 1.53on Euronext Paris of France. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Innate is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.47%. %. The volatility of related hype on Innate Pharma is about 0.0%, with the expected price after the next announcement by competition of 1.53. About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Innate Pharma has Price/Earnings (P/E) ratio of 125.2. The entity recorded a loss per share of 0.27. The firm had not issued any dividends in recent years. Assuming the 90 days trading horizon the next forecasted press release will be uncertain. Check out Innate Pharma Basic Forecasting Models to cross-verify your projections. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.Innate Pharma Related Hype Analysis
Having access to credible news sources related to Innate Pharma's direct competition is more important than ever and may enhance your ability to predict Innate Pharma's future price movements. Getting to know how Innate Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Innate Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GNFT | Genfit | 0.00 | 0 per month | 4.28 | 0 | 5.03 | (6.49) | 24.23 | |
| NANO | Nanobiotix SA | 0.00 | 0 per month | 0.00 | (0.11) | 5.66 | (5.04) | 18.72 | |
| ALCLS | Cellectis | 0.00 | 0 per month | 0.00 | (0.19) | 2.89 | (3.05) | 8.30 | |
| AB | AB Science SA | 0.00 | 0 per month | 0.00 | (0.19) | 3.06 | (4.08) | 10.77 |
Innate Pharma Additional Predictive Modules
Most predictive techniques to examine Innate price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Innate using various technical indicators. When you analyze Innate charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Innate Pharma Predictive Indicators
The successful prediction of Innate Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Innate Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Innate Pharma based on analysis of Innate Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Innate Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Innate Pharma's related companies.
Story Coverage note for Innate Pharma
The number of cover stories for Innate Pharma depends on current market conditions and Innate Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Innate Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Innate Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Innate Pharma Short Properties
Innate Pharma's future price predictability will typically decrease when Innate Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Innate Pharma often depends not only on the future outlook of the potential Innate Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innate Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.9 M | |
| Cash And Short Term Investments | 119.8 M |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |